Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enzo Biochem (ENZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 191,510
  • Shares Outstanding, K 47,170
  • Annual Sales, $ 107,800 K
  • Annual Income, $ -2,500 K
  • 36-Month Beta 0.93
  • Price/Sales 1.76
  • Price/Cash Flow 170.93
  • Price/Book 2.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.95 +3.04%
on 08/08/18
5.01 -18.76%
on 07/18/18
-0.84 (-17.11%)
since 07/17/18
3-Month
3.95 +3.04%
on 08/08/18
6.89 -40.93%
on 05/18/18
-2.71 (-39.97%)
since 05/17/18
52-Week
3.95 +3.04%
on 08/08/18
11.50 -64.61%
on 09/05/17
-6.93 (-63.00%)
since 08/17/17

Most Recent Stories

More News
Market Trends Toward New Normal in Sandy Spring, Tupperware Brands, Dolby Laboratories, AeroVironment, Barnes Group, and Enzo Biochem -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sandy Spring Bancorp, Inc....

ENZ : 4.07 (+0.25%)
B : 67.58 (+0.76%)
AVAV : 84.47 (+1.10%)
SASR : 39.37 (+0.33%)
DLB : 69.02 (+0.44%)
TUP : 33.46 (+0.03%)
Blog Exposure - Bruker Buys Dutch Milk Analysis Equipment Manufacturer Lactotronic to Expand its Presence in the Dairy Industry

Stock Monitor: Enzo Biochem Post Earnings Reporting

ENZ : 4.07 (+0.25%)
Enzo Biochem Reports Third Quarter Results

Enzo Biochem Inc. (NYSE:ENZ), an integrated diagnostic company, today reported results for the third fiscal quarter and nine months ended April 30, 2018, in addition to noting significant...

ENZ : 4.07 (+0.25%)
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2018 Results Tuesday, June 12, 2018 at 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 third quarter results Tuesday, June 12, 2018, at 8:30 AM E.T.

ENZ : 4.07 (+0.25%)
Patent Trial and Appeal Board Denies Hologic Challenge to Enzo Biochem Patent Involved in Delaware Infringement Case

Enzo Biochem, Inc. (NYSE:ENZ) and its subsidiary Enzo Life Sciences, Inc. today announced that the Patent Trial and Appeal Board has denied a petition filed by Hologic, Inc. (NASDAQ:HOLX)...

ENZ : 4.07 (+0.25%)
HOLX : 38.33 (+0.45%)
Exploring Fundamental Drivers Behind Enzo Biochem, RPX, The Hackett Group, 2U, AK Steel Holding, and Och-Ziff Capital Management Group -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enzo Biochem, Inc. (NYSE:ENZ),...

ENZ : 4.07 (+0.25%)
OZM : 1.95 (-1.52%)
HCKT : 18.76 (-0.53%)
AKS : 4.37 (+3.07%)
TWOU : 79.06 (+1.46%)
RPXC : 10.49 (+0.10%)
Enzo Biochem Announces NYS Department of Health's Approval of a New Women's Health Infectious Disease Panel

--Furthers Enzo's Development Program of Robust, Medically Relevant & Affordable Molecular Diagnostic Products and Services Addressing the Clinical Lab Industry's Financial Pressures

ENZ : 4.07 (+0.25%)
Earnings Review and Free Research Report: Enzo Biochem's Q4 and Annual Top-line Rise on a Y-o-Y Basis

LONDON, UK / ACCESSWIRE / October 10, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Enzo Biochem, Inc. (NYSE: ENZ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=ENZ,...

ENZ : 4.07 (+0.25%)
Investor Network: Enzo Biochem, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Enzo Biochem, Inc. (NYSE: ENZ) will be discussing their earnings results in their Q4 Earnings Call to be held September 28, 2017 at 8:30 AM Eastern Time....

ENZ : 4.07 (+0.25%)
Enzo Biochem Reports Increase in Revenues and Profitable Fourth Quarter

Enzo Biochem Inc. (NYSE:ENZ) today reported increased results for the fourth quarter and fiscal year ended July 31, 2017, along with advances in its corporate strategy in molecular diagnostics...

ENZ : 4.07 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ENZ with:

Business Summary

Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo...

See More

Key Turning Points

2nd Resistance Point 4.22
1st Resistance Point 4.14
Last Price 4.07
1st Support Level 4.00
2nd Support Level 3.94

See More

52-Week High 11.50
Fibonacci 61.8% 8.62
Fibonacci 50% 7.72
Fibonacci 38.2% 6.83
Last Price 4.07
52-Week Low 3.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar